121 results about "EDARADD" patented technology

The invention provides methods and materials that use observation of DNA characteristics to obtain information relating to the age of individuals. The instant disclosure identifies 88 sites in or near 80 genes for which the degree of cytosine methylation in epithelial and/or white blood cells is significantly correlated with age. In illustrative embodiments of the invention, cytosine methylation patterns the promoters of the EDARADD, TOMILI, and NPTX2 genes are used to predict the age of an individual with a high degree of accuracy.

The invention discloses a mutant human plasminogen kringle5 gene mK5 and an amplification primer of the mK5 gene, the mutant human plasminogen kringle5 gene modified by adding glutathione-S-transferase before the gene mK5, and a method for preparing protein mK5 recombinant protein of two gene codes, glutathioneS transferase (GST)-mK5 fusion protein and two proteins, wherein the mK5 gene and the GST-mK 5 gene can be applied to preparing medicaments for treating angiogenesis diseases. By the invention, the number of exogenous amino acid in the recombinant K5 protein molecules obtained by a gene engineering method is remarkably reduced, the K5 bioactivity of the obtained mK5 is improved, while the mK5 activity of the GST-mK5 fusion protein is maintained, the stability and water solubility of the protein are improved, the purification steps of an expressed product are simplified, and the purity of the product is improved.

The invention relates to the method of gene fixed-point mutation which is a modified overlap extension PCR method and the mutated gene. The process includes the fragment composition, the double mixing, the prepared extension, the whole DNA composition and after extension. The method is detected by the synzyme gene sam1 from the SAM of the Saccharomyces cerevisiae and gets the mutated gene modified by the rare coden. The SAM synzyme encoding by the gene can express in the yeast and improves the yield of the intracellular SAM. The invention can reach the many fixed-point mutations in a same reaction process.

The invention discloses a goldfish autonomous transposon gene gfTol2, which has a nucleotide sequence shown as SEQ ID No:1. The invention also discloses a transposase coded by the gene gfTol2, which has an amino acid sequence shown as SEQ ID No:2. The invention also discloses use of the gene gfTol2 as a gene medicament or a gene reagent for goldfish; and the rate of graded product of the goldfish is improved and offspring mutation is induced by adjusting the concentration of a transcription product of the gene.

The invention discloses a serum protein marker for early screening and diagnosis of breast cancer, which belongs to the technical field of biomedicine. The serum protein marker for early screening anddiagnosis of the breast cancer is any one or a combination of two or more of the proteins encoded by the CEBPA, RalA, p62, PTCH1, BRCA2, HRAS, FUBP1, GATA3, FGFR3, ALK, HISTIH3B or p53 genes. The invention also discloses a kit and a detection method including the serum protein marker for early screening and diagnosis of the breast cancer. Based on the role played by cancer driver genes in the genesis and development of the tumor, the invention customizes a human protein chip encoded by 138 cancer driver genes, which contains 180 human-derived recombinant proteins. Firstly, an early detectionserum marker of the breast cancer is first screened through the protein chip; then verification is performed by using the ELISA indirect method; and finally, a group of breast cancer serum protein marker that can be used for early screening and diagnosis of the breast cancer is screened out. The area under the ROC curve of the combined diagnosis of breast cancer reaches 0.886; the 95% CI is 0.847to 0.925; and when the specificity is ensured to be 92.2%, the sensitivity is 67.9%, and the consistency rate reaches 80.1%.

The invention discloses a serum protein marker for gastric cancer early screening and diagnosis, belonging to the technical field of biomedicine. The serum protein marker is any one of or combinationof more than two of proteins coded by TP53, GNAS, PBRM1, SRSF2, SMARCB1, GNA11, ACVR1B, PIK3CA and COPB1. Meanwhile, a kit and a detection method of the serum protein marker are also provided. According to the serum protein marker, the kit and the detection method provided by the invention, based on function of a cancer driving gene in occurrence and development of tumors, a human protein chips coded by 138 cancer driving gene is customized, totally, 180 humanized recombinant proteins are contained, firstly, an early detection serum marker for gastric cancer is screened out primarily through the protein chip, then, verification is executed through an ELISA indirect experiment, a group of gastric cancer serum markers available for gastric cancer early screening and diagnosis is screened out, and the gastric cancer serum markers are combination of proteins coded by the TP53, the SRSF2, the SMARCB1 and the GNA11 genes, and combined gastric cancer diagnosis area under the RCO curve of thegastric cancer serum markers is as high as 0.950, 95% CI is 0.925-0.976, when specificity is guaranteed to be 90.70%, sensitivity is 86.83%, and consistency rate is as high as 80.3%.

The invention discloses a litchi disease-resistant gene LcLTP as well as an encoding protein and application thereof. A litchi disease resistance related gene LcLTP is separated from litchis, the full-length cDNA of the gene is 342bp, and the nucleotide sequence of the gene is as shown in SEQ ID NO: 1; the protein coded by the gene is a lipid transfer protein with the full length consisting of 113 amino acids, and the amino acid sequence is shown as SEQ ID NO: 2. Transcription pattern analysis and plant expression analysis find that the LcLTP gene can improve the resistance of plants to phytophthora, so that the litchi disease-resistant gene LcLTP can be applied to the aspect of improving the disease resistance of the plants or breeding disease-resistant plants.

The invention discloses a garrupa MHC (Major Histocompatibility Complex) IIB gene as well as a cloning method and application thereof. The nucleotide sequence of the garrupa MHC IIB gene is shown as SEQ ID NO:1, and the amino acid sequence of protein encoded by the gene is shown as SEQ ID NO:2. In the invention, by using a homologous cloning method, the MHC IIB gene is separated from garrupa, 12 different MHC IIB gene types are identified, the correlation between the polymorphism and the disease resistance of the MHC IIB gene are analyzed, and 6 molecular marks of the MHC IIB gene relevant to the disease resistance of the garrupa are screened; and the cloning method is suitable for screening the marks relevant to the disease resistance of the garrupa and breeding disease-resistant species.

The present invention relates to an infectious particle having a surface displaying a ligand binding to a CD4 receptor for selectively infecting dividing CD4⁺ cells, said particle comprising: (a) one or more structural proteins, and (b) a vector containing a gene of interest functional in a CD4⁺ cell, said gene of interest encoding a Forkhead box protein 3 or a protein inducing expression of Forkhead box protein 3 in the CD4⁺ cell.

The invention belongs to the technical field of genes and especially relates to application of a gene Loc_Os01g12810. The gene Loc_Os01g12810 can be applied to rice chloroplast development regulationmechanism researches; a gene method is utilized to regulate an expression level of the gene Loc_Os01g12810 to research rice chloroplast development regulation mechanisms; a nucleotide sequence of thegene Loc_Os01g12810 is shown in SEQ ID NO:1 in a sequence table; an amino acid sequence of encoding protein of the gene Loc_Os01g12810 is shown in SEQ ID NO:2 in the sequence table. According to the application of the gene Loc_Os01g12810 disclosed by the invention, that the rice gene Loc_Os01g12810 is a gene related with rice chloroplast development is proved for the first time. The Loc_Os01g12810is a PPR gene. Cloning and biological function verification of the gene have important reference significance in rice chloroplast development molecule mechanism researches and researches on effects of PPR family gene in rice development.

The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases.

The invention relates to a rice receptor kinase gene OsRLCK21, a protein encoded by the rice receptor kinase gene OsRLCK21 and application. A nucleotide sequence of the rice receptor kinase gene OsRLCK21 is shown as SEQ ID NO.2, and a protein sequence encoded by the gene is shown as SEQ ID NO.1. The OsRLCK21 gene in rice is knocked out through CRISPR/Cpf1 technology in a fixed-point mode to perform a function study of the gene, a result shows that the rice knocked out of the OsRLCK21 gene has significantly improved resistance to Xanthomonas oryzae IV and GD1358, IV lesion length is shortened by 26.4%-48.8%, C5 lesion length is shortened by 43%-52.3%, rice gene mutations can be caused by inserting or deleting a 503 position to a 508 position in a sequence shown SEQ ID NO.2, and a trait of increased resistance to Xanthomonas oryzae is shown.

This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.

The invention provides a gene, which is a deoxyribonucleic acid (DNA) molecule with the sequence of nucleotide illustrated as the SEQ ID NO:1. A fusion protein of the gene code and a preparation method and application thereof are further provided. The fusion protein mm CTLA4Ig can prevent a CD 28 molecule from being combined with a B7 molecule, further suppresses activation of a T cell, has an obvious immunosuppression function, can be used for preparing an immunosuppressive agent, and is particularly suitable for the immunosuppressive agent for rhesus monkeys.

A light chain variable region gene resisting the CD 20 monoclonal antibody HI47 mutation, the polypeptide coded by said gene, and the application of the fusion protein containing said gene and polypeptide in preparing the medicines for diagnosing and treating tumor are disclosed. The purified expression product of said mutant has the activity to combine with Raji cells expressing CD20 antigen. Its expression product and activity are increased.

Provided is a gene related to astaxanthin accumulation in haematococcus pluvialis and a screening method of the gene. The gene is HpHDR, the sequence length of the gene is 1421bp, and the gene sequence is as shown in SEQ NO.1; HpHDR protein coded through the gene HpHDR is composed of 434 amino acid residues, the molecular formula is C2129H3363N601O656S24, the molecular weight is about 48.64 KD, the theoretical isoelectric point is 6.53, a spatial structure of the protein comprises 15 alpha-helical structures and 12 beta-folded structures, and the amino acid sequence is as shown in SEQ NO.2. The invention provides the screening method of the gene HpHDR, the screening method is high in sensitivity, can detect more samples and is high in screening speed and easy to operate.

Provided are a HNF-1 α gene including a novel single-nucleotide polymorphism and a protein encoded by the HNF-1 α gene, a polynucleotide associated with MODY3 diabetes based on the HNF-1 α gene, a microarray and a diagnostic kit including the polynucleotide, and a method for diagnosis of MODY3 diabetes.

The invention provides a PgJAR1 gene for adjusting ginsenoside synthesis as well as an encoded protein and application of the PgJAR1 gene. The sequence of the PgJAR1 gene for adjusting ginsenoside synthesis is shown as SEQ ID NO.1, and the amino acid sequence of the encoded protein of the PgJAR1 gene for adjusting ginsenoside synthesis is shown as SEQ ID NO.2. The invention further provides a preparation method of the PgJAR1 gene for adjusting ginsenoside synthesis. The protein coded by the PgJAR1 gene has an I-type GH3 protein family conserved sequence, belongs to a GH3 gene family in an auxin enzymatic reaction gene, and is jasmonic acid synthase (JAR). The constructed PgJAR1 gene overexpression vector is subjected to agrobacterium-mediated transformation of ginseng callus to obtain PgJAR1 gene overexpressed ginseng cells, the PgJAR1 gene is utilized to regulate the content of endogenous jasmonic acid-isoleucine (JA-Ile) in the ginseng cells so as to regulate the expression of multiple enzyme genes in ginsenoside biosynthesis, the content of JA-Ile is remarkably increased, and the content of JA-Ile is remarkably increased. Further, synthesis and accumulation of ginsenoside are efficiently promoted. The PgJAR1 gene has an important application value in the aspects of increasing the yield of ginsenoside and improving the quality of the ginseng by utilizing the PgJAR1 gene in the ginseng.

The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases.

The invention discloses use of an SLC17A5 gene and a coded protein thereof in preparing medicines for treating or diagnosing nitrate transfer or metabolic block or disorder related diseases. According to the use disclosed by the invention, a mass of experiments finally confirm that the SLC17A5 gene coded protein (Sialin protein) is a mammal nitrate transfer protein, and the SLC17A5 gene or the coded protein thereof can be used for preparing medicines for treating in vivo nitrate transfer and metabolic block related diseases as well as anti-hypertension and antishock medicines and medicines for treating myocardial infarction and preventing gastric ulcer and the like.

The invention discloses an autosomal dominant Dnajc17 gene mutant as well as application, a diagnostic kit and a diagnostic gene chip thereof. The mutation site of the autosomal dominant Dnajc17 genemutant is that the 401st nucleotide A of a Dnajc17 gene coding region on the human fifteenth chromosome is mutated into C (c.401A>C), so that the 134th amino acid of the protein sequence is mutated into alanine A (p.E134A) from glutamic acid E. Exome sequencing analysis and animal experiment verification are carried out on deafness family members; the Dnajc17 is found to have obvious correlation with the deafness occurrence, and is an important precipitating factor of hereditary hearing loss. The invention provides the diagnostic kit and the diagnostic gene chip for early diagnosis and early intervention treatment of deafness diseases, the diagnostic kit and the diagnostic gene chip have great clinical application value, and the diagnostic kit and the diagnostic gene chip can be used for screening high-risk groups with deafness diseases.